Trastuzumab-strf Gets FDA Approval in Overexpressing Breast and Gastric Cancers
Trastuzumab-strf (HLX02; Hercessi) a monoclonal antibody biosimilar, has been approved as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or …